<DOC>
	<DOCNO>NCT01773148</DOCNO>
	<brief_summary>The goal study assess safety effectiveness AXERA Access System subject undergoing Common Femoral Artery ( CFA ) access Percutaneous Coronary Intervention ( PCI ) and/or Peripheral Vascular Intervention ( PVI ) 5 French ( F ) 6F introducer sheath .</brief_summary>
	<brief_title>Access Safety Efficacy Post Endovascular Intervention</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Subject 18 year age old . Subject clinically indicate PCI PVI involve access 5F 6F introducer sheath femoral artery . Subject able ambulate without assistance prior procedure expect ambulate ( 20 foot ) within 2 hour post procedure . Female subject child bear potential must negative pregnancy test . Subjects pregnant lactating . Subject preexist severe noncardiac systemic disease/illness another reason result project life expectancy le 1 year . Subject active systemic cutaneous infection inflammation ( e.g. , septicemia time procedure ) . Subject systemic hypertension unresponsive treatment ( &gt; 180mmHg systolic &gt; 110mm diastolic ) . Subject significant bleeding coagulopathy platelet disorder , ( INR &gt; 2.0 ) , include know thrombocytopenia ( platelet count &lt; 100,000/µL ) , thrombasthenia , Von Willebrand 's disease , Factor V deficiency , anemia ( hemoglobin &lt; 10 g/dL , hematocrit &lt; 30 % ) . Subject present chronic renal insufficiency ( creatinine ≥3.0mg/dl ) . Subject present hemodynamic instability need emergent surgery emergent procedure . Subject present ST elevation myocardial infarction . Subject present unstable angina nonST elevation myocardial infarction troponin level &gt; 3 X upper limit normal . There must least one troponin level drawn &gt; 6 hour onset chest pain . Subject receive low molecular weight heparin &lt; 8 hour vascular access , glycoprotein IIb/IIIa inhibitor &lt; 24 hour vascular access , unfractionated heparin infusion &lt; 1 hour vascular access , parenteral heparin anticoagulant dose ( opposed DVT prophylaxis ) &lt; 6 hour vascular access . Subjects clinically obese , define BMI &gt; 40 . Subject receive femoral artery Vessel Closure Implant ( VCI ) ( suture staple ) target access site . Subject receive femoral artery VCI ( collagen/PEG/PGA ) target access site within 90 day AXERA procedure . Subject unable routinely walk least 20 foot without assistance ( e.g. , require walker wheelchair mobilize , leg amputee know paralysis ) unable ambulate within 2 hour post procedure . Subject prior vascular surgery vascular graft target femoral artery access site . Subject previous target femoral artery complication angiography ( pseudoaneurysm , Arteriovenous ( AV ) fistula , dissection ) , small CFA , abnormal , absent weak distal ipsilateral pulse , present clinically significant peripheral vascular disease vicinity puncture . Subject high puncture ( i.e . inferior reflection inferior epigastric artery ) . Subject antegrade puncture . Subject stent ipsilateral common femoral artery . Subject currently participate investigational drug another device study clinically interfere current study endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>